CompletedNot Applicable

EUSOL vs. PDGF Dressing for Diabetic Foot Ulcers

Pakistan120 participantsStarted 2020-01-01

Plain-language summary

Diabetic foot ulcers are a major cause of morbidity and amputation. This randomized controlled trial will compare the efficacy of a traditional antiseptic dressing (EUSOL) with a modern biologic dressing containing Platelet-Derived Growth Factor (PDGF) in promoting wound contraction. The study aims to determine if PDGF dressing leads to better healing outcomes in patients with Grade II Wagner diabetic foot ulcers.

Who can participate

Age range30 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of diabetes mellitus. * Presence of a Grade II Wagner diabetic foot ulcer (penetrating to subcutaneous tissue, without involvement of tendon, bone, or joint). * Ulcer size less than 6 x 6 cm at baseline. Exclusion Criteria: * Uncontrolled diabetes * Malnourished (BMI less than 20) * HB less than 10 * ABPI less than 0.9 * Immunosuppression therapy * Patients with malignancy or uncontrolled cardiopulmonary, neurological, or psychiatric disease. * Severe active infection

What they're measuring

Proportion of patients achieving wound contraction.

Timeframe: 4 weeks

Trial details

NCT IDNCT07493343

SponsorServices Hospital, Lahore

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2025-12-31

View on ClinicalTrials.gov More Diabetic Wound trials